Novartis AG ADR (NVS)vsSomalogic Inc (SLGC)
NVS
Novartis AG ADR
$144.62
-1.33%
HEALTHCARE · Cap: $275.95B
SLGC
Somalogic Inc
$9.89
0.00%
HEALTHCARE · Cap: $396.23M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 69131% more annual revenue ($56.58B vs $81.72M). NVS leads profitability with a 23.9% profit margin vs -159.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SLGC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$144.62
$34.84 premium
Margin of Safety
-12.9%
Fair Value
$1.86
Current Price
$9.89
$8.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.7% — below average capital efficiency
Revenue declined 47.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SLGC
SLGC has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : SLGC
The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SLGC is a turnaround play — different risk/reward profiles.
SLGC carries more volatility with a beta of 1.64 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Somalogic Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
SomaLogic Inc. (SLGC) is a pioneering biotechnology company specializing in protein biomarker discovery and analysis, harnessing its proprietary SomaScan® platform to provide insights that advance precision medicine. By utilizing an extensive protein library, the company aims to develop sophisticated diagnostics and therapeutic applications across various health conditions, including cancer, cardiovascular diseases, and metabolic disorders. SomaLogic is positioned at the forefront of the biomarker industry, driving innovation in research and clinical settings while forming strategic partnerships to expand its reach and enhance the adoption of its technologies. With a strong focus on data-driven health solutions, SomaLogic is committed to improving patient outcomes and enabling personalized therapeutic strategies.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?